RNAi: a novel strategy for the treatment of prion diseases
J. Clin. Invest. Qingzhong Kong, et al. 116:3101 doi:10.1172/JCI30663 [Go to this article.]

Figure 1
RNAi and other strategies for prion disease treatment. Monomeric PrP^C (yellow ovals) converts into multimeric PrP^Sc (yellow rectangles) in the process of prion replication and prion pathogenesis. Reagents or strategies that effectively reduce the PrP^C level or interfere with the PrP^C-to-PrP^Sc conversion process have shown therapeutic potential for prion disease. In this issue of the JCI, Pfeifer et al. (20) show that anti-PrP^C shRNA carried on a lentivector is transfected into neuronal or ES cells, integrated into chromosomal DNA, and transcribed; anti-PrP^C shRNA is released into the cytoplasm, where it is processed by endonuclease Dicer into siRNA. This in turn activates the RNA-induced silencing complex (RISC) to degrade PrP mRNAs, leading to reduced expression of PrP^C and consequently diminished PrP^Sc accumulation and significantly improved survival time after prion infection. Other promising reagents and strategies are listed in the top box. Only the most effective and least toxic compounds or chemicals that have demonstrated therapeutic effects in animals after intracerebral prion inoculation are included; a few other reagents and vaccines that have potential but need further research are also listed (5–6).